COMMUNICATION
SCIENTIFIC EXCELLENCE EDUCATION
NETWORKING 

Congratulations to Luigi Naldini, who has been elected as an international member to the NAM.

SR-TIGET–Danaher Symposium, “Unlocking Access: Cell & Gene Therapy at Scale ” is taking place at San Raffaele Hospital in Milan on 9–10 November 2026, marking the 30th anniversary of SR-TIGET. The meeting will bring together leading researchers, clinicians, industry experts and patient representatives to discuss advances in hematopoietic stem cell gene therapy and genome editing, alongside key challenges in safety, manufacturing and sustainable patient access. The symposium w

For more information, clic here

Foundation For Rare Diseases (Fondation Maladies Rares, France) organises an online MOOC on gene and gene-based cell therapies for rare diseases . The course features contributions from leading U.S. and European researchers — including Alain Fischer, Heather Gray Edwards, Alessio Cantore, Zoltan Ivics, Sylvie Odent, Salima Hacein-Bey-Abina, Manuel Gonçalves, Marina Cavazzana, Allison Bradbury, Anne Galy, Chantal Pichon, Claire Booth, Jeffrey Medin , among others — as well a

ESGCT are greatly saddened by the loss of Professor Claudio Bordignon, a pioneer in the gene therapy field, and the first President of the ESGCT.

Last Thursday, the FDA approved the LAD gene therapy developed by Juan A. Bueren and Elena Almarza, in collaboration with the Adrian Thrasher team. This treatment was licensed to Rocket Pharma, who developed the clinical trial and presented it to the FDA. We believe this is terrific news for the gene therapy field and for ESGCT, as all these advances have come from ESGCT members, and the society has played a fundamental role in favouring this collaboration and in the developm

Hosted as part of the AROUND THE WORLD SERIES in collaboration with the Coalition of International Gene Therapy Societies.

The ESGCT would like to congratulate Fondazione Telethon and HSR-TIGET on the milestone achievement of the FDA approval of WAS ex vivo gene therapy. Please see below their statement: We are honoured to share a moment of profound significance for us, for patients, families, and the scientific community. The U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Waskyra , the first gene therapy for the treatment of Wiskott-Aldrich

The 32nd ESGCT Annual Congress took place in collaboration with SETGYC from 7-10 October 2025 at Fibes in Seville. Congress delegates can log in to their online registration portal to access the Congress abstract book, online programme, and Certificate of Attendance. Login here > Abstracts published by Human Gene Therapy will be available soon. Event Statistics (Click to enlarge) We are very grateful for the support of all our sponsors and partners.

Hosted as part of the AROUND THE WORLD SERIES in collaboration with the Coalition of International Gene Therapy Societies.